Beauty Health (SKIN) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Beauty Health is expected to report Q3 2026 results after market close on November 5, with analysts projecting a loss of $1.335 per share and revenue of $67.97 million.
• The company’s previous quarter beat EPS estimates but missed revenue expectations, reporting a $0.40 loss per share and $72.11 million in revenue. Analysts expect full-year EPS of negative $3.18.
• SKIN shares have fallen sharply, opening at $10.49 versus a 12-month high of $34.80. Analysts maintain a consensus “Hold” rating with an average price target of $18.00.

Beauty Health (NASDAQ:SKIN - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($1.3350) per share and revenue of $67.97 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Beauty Health (NASDAQ:SKIN - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10. Beauty Health had a negative return on equity of 47.83% and a negative net margin of 9.79%. The firm had revenue of $72.11 million during the quarter, compared to analyst estimates of $74.45 million. On average, analysts expect Beauty Health to post ($3.18) EPS for the current fiscal year and ($1.16) EPS for the next fiscal year.

Beauty Health Stock Performance

NASDAQ:SKIN opened at $10.49 on Thursday. The stock has a 50-day moving average price of $12.57 and a 200 day moving average price of $17.04. The stock has a market capitalization of $68.26 million, a P/E ratio of -2.38 and a beta of 1.05. Beauty Health has a 12-month low of $9.89 and a 12-month high of $34.80. The company has a current ratio of 1.76, a quick ratio of 1.48 and a debt-to-equity ratio of 4.36.

Analysts Set New Price Targets

SKIN has been the topic of a number of research analyst reports. Zacks Research cut Beauty Health from a "strong-buy" rating to a "hold" rating in a report on Monday, July 20th. Citigroup reaffirmed a "hold" rating on shares of Beauty Health in a report on Thursday, October 15th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Beauty Health in a research report on Wednesday, October 21st. Stifel Nicolaus set a $10.00 price objective on shares of Beauty Health in a research report on Thursday, October 15th. Finally, TD Cowen lowered their target price on shares of Beauty Health from $20.00 to $18.00 and set a "hold" rating on the stock in a report on Wednesday, August 12th. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $18.00.

About Beauty Health

BeautyHealth is a global health and beauty company focused on providing technology, products and services for aesthetic and skincare businesses. Its flagship brand, HydraFacial, offers a non-invasive treatment platform that combines cleansing, exfoliation, extraction and hydration, with treatments delivered through proprietary devices and consumable solutions.

The company also provides professional skincare products, treatment systems and related solutions designed for use by physicians, dermatologists, aestheticians and other licensed practitioners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.